Global Cystic Fibrosis Therapeutics Market 2016-2026

LONDON, November 3, 2016 /PRNewswire/ --

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies

The latest report from business intelligence provider visiongain offers comprehensive analysis of the global cystic fibrosis market. Visiongain expects the global cystic fibrosis market to grow at a CAGR of 16.7% from 2016 to 2021. The global cystic fibrosis market is estimated to reach $7.7bn by 2021.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this 191-page report you will receive 113 tables, charts and graphs - all unavailable elsewhere.

The 191 page report provides clear detailed insight into the global cystic fibrosis market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope 

• Global Cystic Fibrosis market forecasts from 2016-2026

• Cystic Fibrosis submarket forecasts from 2016-2026 covering:
- Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
- Protein Transcription Modulators
- Pancreatic Enzyme Products (PEP)
- Other therapies

To see a report overview please email Sara Peerun on [email protected]

• Individual drug revenue forecasts from 2016-2026 by pharmacological classes:

- Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators:
• Orkambi
• Kalydeco
• VX-661 + ivacaftor
• Second corrector/VX-661/ivacaftor

- Protein Transcription Modulators
• Pulmozyme
• QR-010
• Translarna

- Pancreatic Enzyme Products (PEP)
• Ceron

- Other therapies
• Cayston
• TOBI

• Revenue forecasts from 2016-2026 and discussion of relevant trends and developments in the leading national cystic fibrosis market

• Analysis of the key factors driving growth in the global, regional and country level of the Cystic Fibrosis Market from 2016-2026

• Patent and clinical trials information of the marketed and pipeline products for cystic fibrosis

• The dynamic of pricing, patient share and market share of the leading cystic fibrosis drugs in the US and Europe

• Discussion on selected leading companies marketing and developing cystic fibrosis drugs:
- Vertex Pharmaceuticals
- Roche
- AbbVie
- Gilead Sciences
- Novartis

Visiongain's study is intended for anyone requiring commercial analyses for the Cystic Fibrosis Market and leading companies. You find data, trends and predictions.

Buy our report today: Global Cystic Fibrosis Therapeutics Market 2016-2026: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies

To request a report overview of this report please emails Sara Peerun at [email protected]  or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1749/Global-Cystic-Fibrosis-Therapeutics-Market-2016-2026

List of Companies and Organisations: 

AbbVie

Aradigm

Aurora Biosciences

Bayer

Celtaxsys

Chiesi

Chugai Pharmaceutical Co.

Concert Pharmaceuticals

Corbus Pharmaceuticals

Cyclacel Pharmaceuticals

Demegen

EmphyCorp

EryDel

FDA

Genentech

Genkyotex

Gilead

InDex Pharmaceutials

ManRos Therapeutics

NanoBio

NICE

NIH

Novartis

Novoteris

Ocean Therapeutics

OrPro Therapeutics

Polydex Pharmaceuticals

ProQR Therapeutics

Pulmatrix

Roche

Shire

Teva

The University of Iowa

The University of Wisconsin

The University of Wisconsin System

UCB

University of Maryland

Vectura

Vertex Pharmaceuticals

ViroChem Pharma

XOMA

To see a report overview please email Sara Peerun on [email protected]

SOURCE Visiongain Ltd